[
  {
    "model": "claude-opus",
    "model_id": "claude-opus-4-5-20251101",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "This securities class action alleges that Carvana and its executives engaged in a pump-and-dump scheme by making false statements about the company's growth sustainability, business model advantages, and title/registration compliance. Plaintiffs claim defendants artificially inflated stock prices through unsustainable growth tactics including lowering vehicle purchasing standards, rapid market expansion without infrastructure, and violating state title/registration laws, allowing insiders to sell over $3.87 billion in stock before the truth emerged and stock price collapsed 97%.",
      "claim_rulings": [
        {
          "claim": "Section 10(b) and Rule 10b-5 - Scheme to Defraud and False Statements",
          "ruling": "dismissed",
          "scienter_analysis": "The complaint fails to adequately plead scienter with the particularity required by the PSLRA. While plaintiffs allege substantial insider sales, the sales were made pursuant to 10b5-1 trading plans adopted before many of the alleged problems materialized. The modifications to these plans, while suspicious, do not establish actual knowledge of falsity at the time statements were made. The confidential witness allegations describe operational problems and employee complaints, but do not demonstrate that individual defendants actually knew their public statements were false when made. The allegations that executives attended meetings where problems were discussed are too general - knowing about operational challenges is different from knowing that specific public statements were false. The 'growth at any cost' strategy, while potentially unwise, does not establish fraudulent intent. The complaint relies heavily on hindsight analysis comparing later disclosures to earlier statements, which is insufficient under the PSLRA. The inference that defendants knew their business model was unsustainable is not more compelling than the innocent inference that management genuinely believed in their growth strategy and was surprised by the extent of operational problems. The title/registration issues, while serious, appear to have developed over time rather than being knowingly concealed from the outset."
        },
        {
          "claim": "Section 20(a) Control Person Liability",
          "ruling": "dismissed",
          "scienter_analysis": "Section 20(a) claims are derivative of the underlying Section 10(b) violation. Because the Court has dismissed the Section 10(b) claim for failure to adequately plead scienter, the Section 20(a) control person claims must also be dismissed as there is no underlying primary violation upon which to base control person liability."
        },
        {
          "claim": "Section 20A Insider Trading",
          "ruling": "dismissed",
          "scienter_analysis": "Section 20A claims require an underlying violation of the Exchange Act. Because the Court has dismissed the Section 10(b) claim, the Section 20A insider trading claims fail as well. Moreover, the insider sales were conducted pursuant to 10b5-1 plans, and while plaintiffs criticize the modifications to these plans, they have not adequately alleged that defendants possessed material nonpublic information at the time the plans were adopted or modified with sufficient particularity to establish scienter."
        },
        {
          "claim": "Section 11 of the Securities Act (2022 Public Offering)",
          "ruling": "sustained",
          "scienter_analysis": "Section 11 is a strict liability provision that does not require scienter. Plaintiffs have adequately alleged that the Registration Statement contained material misstatements and omissions regarding the company's business model, logistics capabilities, and title/registration compliance issues that existed at the time of the April 2022 offering. The allegations that the company was already experiencing widespread title/registration violations and operational constraints at the time of the offering, which were not adequately disclosed, state a claim under Section 11."
        },
        {
          "claim": "Section 12(a)(2) of the Securities Act",
          "ruling": "sustained",
          "scienter_analysis": "Like Section 11, Section 12(a)(2) does not require scienter. Plaintiffs have adequately alleged that the Prospectus Supplement contained material misstatements and omissions, and that defendants offered or sold securities by means of this defective prospectus. The claims against the underwriter defendants and issuer are adequately pled."
        },
        {
          "claim": "Section 15 of the Securities Act - Control Person Liability",
          "ruling": "sustained",
          "scienter_analysis": "Because the underlying Section 11 and 12(a)(2) claims survive, the Section 15 control person claims against the Individual Securities Act Defendants are sustained. Plaintiffs have adequately alleged that these defendants controlled Carvana by virtue of their positions as directors and/or senior officers."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 113035,
      "completion_tokens": 995,
      "total_tokens": 114030
    },
    "case_id": "azd-2_22-cv-02126"
  },
  {
    "model": "claude-opus",
    "model_id": "claude-opus-4-5-20251101",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "This securities class action complaint alleges that Elon Musk and Tesla violated Section 10(b) of the Securities Exchange Act and Rule 10b-5 by making false and misleading statements regarding a proposed going-private transaction for Tesla. On August 7, 2018, Musk tweeted 'Am considering taking Tesla private at $420. Funding secured,' along with subsequent statements suggesting the transaction was imminent and only contingent on a shareholder vote. The complaint alleges these statements were false because funding had not been secured, no terms had been agreed upon with any potential investor, and numerous steps necessary for such a transaction had not been taken. The complaint also brings Section 20(a) control person liability claims against Tesla's Board of Directors.",
      "claim_rulings": [
        {
          "claim": "Section 10(b) and Rule 10b-5 against Tesla and Musk",
          "ruling": "sustained",
          "scienter_analysis": "The complaint adequately pleads scienter with particularized facts demonstrating that Musk knew his statements were false when made. First, the complaint alleges specific facts showing Musk's actual knowledge: (1) Musk knew he had only a single 30-45 minute preliminary meeting with the Public Investment Fund on July 31, 2018, where no specific terms were discussed; (2) Musk admitted to the SEC that his statements 'were premised on a long series of baseless assumptions and were contrary to facts that [he] knew'; (3) Musk knew there was 'a lot of uncertainty' about the transaction and believed it had only a 50% likelihood of success; (4) Musk knew he had not discussed the $420 price with any potential funding source and selected it as a marijuana joke for his girlfriend; (5) Musk was told by a private equity expert that his proposed structure was 'unprecedented' and that retail investors likely could not remain shareholders. Second, the complaint alleges strong circumstantial evidence of motive: Musk had a documented campaign against short sellers, having previously tweeted about an imminent 'short burn of the century' and expressing his desire to 'end negative propaganda from shorts.' Third, the SEC filed fraud charges against Musk, which he settled by agreeing not to deny the allegations, paying $20 million, and resigning as Chairman. The consent judgment under SEC Rule 202.5(e) prevents Musk from denying the fraud allegations. These particularized facts create a strong inference of scienter that is more compelling than any innocent explanation. An innocent explanation—that Musk genuinely believed funding was secured based on preliminary discussions—is far less plausible given his own admissions that his statements were 'contrary to facts that he knew' and his acknowledged understanding of the 'uncertainty' surrounding the transaction."
        },
        {
          "claim": "Section 20(a) Control Person Liability against the Board",
          "ruling": "sustained",
          "scienter_analysis": "Because the underlying Section 10(b) and Rule 10b-5 claims against Tesla and Musk are sustained, the derivative Section 20(a) claims against the Board may proceed. The complaint adequately alleges that the Board members were controlling persons of Tesla by virtue of their positions as directors, their authority over Tesla's public disclosures, and their specific control over Musk's Twitter communications (which Tesla had designated as an official channel of company communications in 2013). The complaint alleges the Board had the power to influence and control Tesla's decision-making and the content of public statements, and that Board member Gracias specifically ordered Musk to refrain from tweeting about the transaction after August 7, 2018, demonstrating actual control."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 30049,
      "completion_tokens": 821,
      "total_tokens": 30870
    },
    "case_id": "cand-3_18-cv-04865"
  },
  {
    "model": "claude-opus",
    "model_id": "claude-opus-4-5-20251101",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "This securities class action alleges that Netflix and its executives violated Section 10(b) and Rule 10b-5 of the Securities Exchange Act by making materially false and misleading statements about the company's subscriber growth prospects and market penetration. Plaintiffs claim defendants concealed the true extent of account sharing (password sharing), which resulted in Netflix being far more penetrated in key markets than disclosed. Specifically, plaintiffs allege that while defendants claimed UCAN market penetration was roughly 60%, actual penetration including account sharers was approximately 83-84%. The complaint alleges defendants attributed slowing subscriber growth to COVID-19 pull-forward effects rather than disclosing the material impact of account sharing on acquisition.",
      "claim_rulings": [
        {
          "claim": "Section 10(b) and Rule 10b-5 - Securities Fraud",
          "ruling": "dismissed",
          "scienter_analysis": "The complaint fails to plead particularized facts establishing a strong inference of scienter. The allegations amount to fraud by hindsight - plaintiffs argue that because Netflix eventually disclosed account sharing data in April 2022, defendants must have known this information earlier and intentionally concealed it. However, the complaint lacks specific facts showing defendants knew their statements about market penetration were false when made. Key deficiencies include: (1) The complaint acknowledges Netflix had always been aware of account sharing and publicly discussed it for years, characterizing it as not a 'material inhibitor' to growth - this is inconsistent with intentional concealment; (2) The former employee allegations (FE1 and FE2) do not establish that defendants knew account sharing was materially impacting growth during the Class Period - FE1's memo merely stated Netflix would not crack down on sharing during COVID, and FE2's allegations about internal discussions do not show defendants knew their public statements were false; (3) Defendants' attribution of slowing growth to COVID pull-forward effects was a plausible explanation at the time, and the complaint does not adequately allege defendants knew this explanation was false rather than simply mistaken; (4) The testing of account-sharing restrictions beginning in 2021 does not establish scienter - companies routinely test features without knowing the ultimate impact on their business; (5) Netflix's risk disclosures warned that account sharing could impact growth, undermining any inference of intentional concealment; (6) The inference that defendants were merely wrong about the relative impact of COVID versus account sharing on subscriber growth is at least as compelling as an inference of fraud. Innocent explanations - including genuine uncertainty about the causes of slowing growth during an unprecedented pandemic - are equally or more plausible than fraudulent intent."
        },
        {
          "claim": "Section 20(a) - Control Person Liability",
          "ruling": "dismissed",
          "scienter_analysis": "Section 20(a) claims against the Individual Defendants must be dismissed because they are derivative of the Section 10(b) claim. Since the complaint fails to adequately plead an underlying violation of Section 10(b) due to insufficient scienter allegations, the control person liability claims necessarily fail as well. There can be no control person liability absent a primary securities violation."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 47981,
      "completion_tokens": 695,
      "total_tokens": 48676
    },
    "case_id": "cand-4_22-cv-02672"
  },
  {
    "model": "claude-opus",
    "model_id": "claude-opus-4-5-20251101",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "This securities class action complaint alleges that Talis Biomedical Corporation and its officers made materially false and misleading statements about the company's COVID-19 diagnostic device (Talis One) in connection with its February 2021 IPO and subsequent public statements. Plaintiffs allege defendants concealed that: (1) Talis used an insufficiently sensitive comparator assay in its FDA EUA submission, which was quickly rejected; (2) the Talis One suffered from high invalid rates and design defects; and (3) Talis could not manufacture the device at scale despite claims of being 'ready to go.' The complaint brings claims under Sections 11 and 15 of the Securities Act (strict liability/negligence) and Sections 10(b) and 20(a) of the Exchange Act (fraud).",
      "claim_rulings": [
        {
          "claim": "Section 11 of the Securities Act (against Securities Act Defendants)",
          "ruling": "sustained",
          "scienter_analysis": "Section 11 claims are strict liability claims that do not require scienter. The complaint adequately alleges material misstatements and omissions in the Registration Statement concerning: (1) the flawed comparator assay used in the EUA submission; (2) the Talis One's high invalid rates and design issues; and (3) manufacturing capabilities. These are allegations of present or historical facts, not forward-looking statements, and the PSLRA safe harbor expressly excludes statements made in connection with an IPO."
        },
        {
          "claim": "Section 15 of the Securities Act (against Individual Defendants)",
          "ruling": "sustained",
          "scienter_analysis": "Section 15 control person liability does not require scienter. The complaint adequately alleges that the Individual Defendants were officers and directors who signed the Registration Statement and had the power to control Talis's actions. With the underlying Section 11 violation sustained, the derivative Section 15 claims survive."
        },
        {
          "claim": "Section 10(b) and Rule 10b-5 of the Exchange Act (against Exchange Act Defendants)",
          "ruling": "dismissed",
          "scienter_analysis": "The complaint fails to plead scienter with the particularity required by the PSLRA. While plaintiffs allege former employees stated that management 'knew' of problems, these allegations are conclusory and lack specific facts showing what individual defendants actually knew at the time of each challenged statement. The allegations that CEO Coe was 'briefed' about timeline issues and that management received user study feedback are vague and do not establish that defendants knew their specific public statements were false when made. The former employee allegations (FE-1 through FE-5) describe general corporate dysfunction but do not provide particularized facts demonstrating that the Officer Defendants possessed actual knowledge of falsity. The circumstantial evidence of scienter - executive departures, the Talis One being the company's core product, and reporting requirements under contracts - creates at most an inference of negligence or mismanagement, not fraudulent intent. Innocent explanations (aggressive but good-faith optimism, evolving technical challenges, legitimate business judgment about timelines) are at least as compelling as the inference of fraud. The 'core operations' doctrine alone is insufficient to establish scienter absent specific facts showing what defendants knew."
        },
        {
          "claim": "Section 20(a) of the Exchange Act (against Officer Defendants)",
          "ruling": "dismissed",
          "scienter_analysis": "Section 20(a) control person liability is derivative of an underlying securities violation. Because the Section 10(b) and Rule 10b-5 claims are dismissed for failure to adequately plead scienter, the Section 20(a) claims must also be dismissed."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 44064,
      "completion_tokens": 827,
      "total_tokens": 44891
    },
    "case_id": "cand_22_cv_00105"
  },
  {
    "model": "claude-opus",
    "model_id": "claude-opus-4-5-20251101",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "This is a securities class action against Lucid Group, Inc. and its executives (CEO Peter Rawlinson and CFO Sherry House) alleging violations of Section 10(b) and Rule 10b-5 of the Securities Exchange Act, as well as Section 20(a) control person liability. Plaintiffs allege defendants made materially false and misleading statements about Lucid's ability to produce electric vehicles, repeatedly affirming production targets of 20,000 vehicles for 2022 while knowing internally the company would produce less than 10,000 due to severe internal logistics problems including dysfunctional inventory systems, warehouse overcapacity, inability to get parts to production lines, and design flaws. The complaint alleges defendants concealed these internal issues while blaming external industry-wide supply chain challenges, and that the stock price declined significantly when the truth was revealed through guidance cuts on February 28, 2022 and August 3, 2022.",
      "claim_rulings": [
        {
          "claim": "Count I - Violation of Section 10(b) of the Exchange Act and SEC Rule 10b-5 against all Defendants",
          "ruling": "sustained",
          "scienter_analysis": "The complaint adequately pleads scienter with particularized facts creating a strong inference of fraudulent intent. First, FE-2 alleges that in October or early November 2021, Rawlinson personally stated at a meeting that Lucid would produce less than 10,000 vehicles in 2022 and instructed attendees to keep this confidential - directly contradicting the 20,000 unit guidance publicly affirmed on November 15, 2021. Second, multiple former employees (FE-1, FE-2, FE-5, FE-6, FE-8, FE-10) provide particularized allegations that Rawlinson was repeatedly informed of severe internal logistics problems through personal visits to the warehouse and plant, daily reports, and meetings where these issues were discussed. FE-1 personally told Rawlinson in September and November 2021 about warehouse problems and that Lucid would never meet production goals. Third, Rawlinson had strong motive - his performance-based RSUs worth potentially $556 million were tied to maintaining market capitalization targets, and he ultimately received approximately $263 million in stock options by keeping the stock price artificially inflated through January 2022. Fourth, House attended a July 2021 meeting where inventory problems were discussed and denied requests for physical inventory counts because management did not want to impact Lucid's 'books.' Fifth, the temporal proximity between repeated guidance affirmations and subsequent drastic cuts (20,000 to 12,000-14,000 to 6,000-7,000) supports scienter. The allegations go beyond conclusory statements or fraud by hindsight - they include specific meetings, dates, participants, and contemporaneous internal admissions that directly contradict public statements. While innocent explanations may exist, the particularized facts about Rawlinson's internal admission of less than 10,000 vehicles while publicly affirming 20,000, combined with his substantial financial motive and direct knowledge of logistics problems, create a strong inference of scienter that is at least as compelling as any opposing inference."
        },
        {
          "claim": "Count II - Violation of Section 20(a) of the Exchange Act against Individual Defendants (Rawlinson and House)",
          "ruling": "sustained",
          "scienter_analysis": "Because the underlying Section 10(b) claim survives, the Section 20(a) control person liability claim also survives. The complaint adequately alleges that Rawlinson (CEO/CTO) and House (CFO) were controlling persons of Lucid by virtue of their senior executive positions, their direct involvement in day-to-day operations, their power to control corporate policies and practices, their access to nonpublic information, and their direct involvement in making the alleged false statements. The complaint also adequately alleges their culpable participation in the fraud through their knowing or reckless conduct as detailed in the scienter analysis for Count I."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 84295,
      "completion_tokens": 918,
      "total_tokens": 85213
    },
    "case_id": "cand_22_cv_02094"
  },
  {
    "model": "claude-opus",
    "model_id": "claude-opus-4-5-20251101",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "This securities class action alleges that Cutera, Inc. and its executives violated Section 10(b) and Rule 10b-5 by making materially false statements about the company's internal controls, inventory management, and the success of its AviClear product rollout. Plaintiffs claim defendants concealed inventory control failures, quality problems, and that the AviClear launch diverted resources from core business segments, ultimately leading to financial restatements and significant stock price declines.",
      "claim_rulings": [
        {
          "claim": "Section 10(b) and Rule 10b-5 against all Defendants",
          "ruling": "sustained",
          "scienter_analysis": "The complaint adequately pleads scienter with particularized facts. First, multiple confidential witnesses (CWs) provide specific accounts that executives including CEO Mowry were directly informed of inventory control problems, supply chain issues, and AviClear failures. CW 1 states Mowry knew about inventory problems because Batarseh, Eckerman, and Sennett directly told him that Pinapati's inventory estimates were wrong. CW 8 indicates customers sent complaints about downed systems directly to Mowry. CW 4 states it was 'impossible' for Mowry and Huffman not to know about delivery problems discussed in company-wide townhall meetings where Mowry was present. Second, the AviClear Incentive Plan created a strong motive for fraud - executives received performance stock units tied to device placements rather than actual utilization, incentivizing them to rush devices into the field regardless of customer satisfaction. The Board later found Plants was 'far more interested in his own personal enrichment than in leading the Company for the benefit of all stakeholders.' Third, the terminations 'with cause' of Mowry and Plants, explicitly linked by the Special Committee to the failed AviClear execution and Mowry's failure to 'appropriately train and incentivize sales teams, accurately forecast demand and usage,' strongly supports scienter. Fourth, defendants signed SOX certifications attesting to effective internal controls while the company lacked basic inventory controls - CW 6 described how anyone could walk into the warehouse and take parts without controls. The subsequent restatement of Q1 and Q2 2023 financials demonstrates the falsity of these certifications. The combination of direct knowledge from multiple sources, financial motive, contemporaneous terminations for cause linked to the fraud, and false SOX certifications creates a strong inference of scienter that is cogent and at least as compelling as any opposing inference."
        },
        {
          "claim": "Section 20(a) Control Person Liability against Individual Defendants",
          "ruling": "sustained",
          "scienter_analysis": "Because the underlying Section 10(b) claim is sustained, the derivative Section 20(a) claim also survives. The complaint adequately alleges the Individual Defendants were controlling persons who participated in the operation and management of Cutera, held senior positions giving them knowledge of material information, had the ability to control the contents of public filings and statements, and exercised their power and authority to cause the company to engage in the alleged wrongful conduct."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 73929,
      "completion_tokens": 710,
      "total_tokens": 74639
    },
    "case_id": "cand_23_cv_02560"
  },
  {
    "model": "claude-opus",
    "model_id": "claude-opus-4-5-20251101",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "This securities class action alleges that Rain Oncology and its executives made materially false and misleading statements regarding the company's clinical trial strategy for milademetan, specifically by representing that Phase 1 trial data supported skipping Phase 2 trials and proceeding directly to Phase 3 (Phase 2 Bypass), when in fact the drug did not meet the criteria for such bypass and the decision represented an extreme departure from industry standards. The complaint alleges violations of Section 10(b) and Rule 10b-5 of the Exchange Act, Section 20(a) control person liability, and Sections 11 and 15 of the Securities Act.",
      "claim_rulings": [
        {
          "claim": "Count I - Violation of Section 10(b) and Rule 10b-5 against Rain, Vellanki, and Bryce",
          "ruling": "dismissed",
          "scienter_analysis": "The complaint fails to plead particularized facts establishing a strong inference of scienter. The allegations amount to 'fraud by hindsight' - plaintiffs allege defendants knew the Phase 2 Bypass was risky because the Phase 3 trial ultimately failed. However, the complaint does not allege specific facts showing defendants actually knew their statements were false when made. The core allegation is that defendants made a strategic business decision to skip Phase 2 trials that plaintiffs characterize as 'reckless' based on industry norms and academic literature. This is insufficient. The complaint acknowledges Phase 2 Bypass is permissible in certain circumstances, and defendants' belief that their data supported this approach - even if ultimately proven wrong - does not establish fraud. The former employee (FE1) allegations are conclusory, stating only that Vellanki and Bryce 'understood' the data and its limitations, which actually supports that they made an informed business judgment rather than committed fraud. The SEC correspondence regarding the registration statement shows defendants complied with SEC requests and does not demonstrate knowledge of falsity regarding the Phase 2 Bypass decision itself. The allegation that defendants needed capital and wanted to be first-to-market establishes motive common to all companies, not particularized evidence of fraudulent intent. An innocent explanation - that defendants genuinely believed the Phase 1 data supported advancing to Phase 3 - is at least as compelling as the inference of fraud."
        },
        {
          "claim": "Count II - Violation of Section 20(a) of the Exchange Act against Vellanki and Bryce",
          "ruling": "dismissed",
          "scienter_analysis": "Section 20(a) control person liability is derivative of an underlying securities violation. Because the Section 10(b) and Rule 10b-5 claim is dismissed for failure to adequately plead scienter, the Section 20(a) claim must also be dismissed as there is no predicate violation upon which control person liability can be based."
        },
        {
          "claim": "Count III - Violation of Section 11 of the Securities Act against Rain and Director Defendants",
          "ruling": "sustained",
          "scienter_analysis": "Section 11 claims do not require scienter - they are essentially strict liability claims for material misstatements or omissions in registration statements. Plaintiffs have adequately alleged that the registration statement and prospectus contained material misstatements regarding the Phase 1 data 'validating' the dosing schedule and supporting the Phase 2 Bypass, when the Phase 1 trial actually identified only a 'recommended Phase 2 dose' for further testing. Plaintiffs have also adequately alleged that the registration statement failed to disclose the significant risks associated with the Phase 2 Bypass as required by Item 105 of Regulation S-K, given that milademetan did not have a well-characterized mechanism of action or safety profile. The allegations that the Phase 2 Bypass deviated from industry standards, academic literature, and even Daiichi Sankyo's own clinical trial plans are sufficient to state a claim that the risk disclosures were inadequate."
        },
        {
          "claim": "Count IV - Violation of Section 15 of the Securities Act against Director Defendants",
          "ruling": "sustained",
          "scienter_analysis": "Section 15 control person liability under the Securities Act is derivative of a Section 11 violation. Because the Section 11 claim is sustained, the Section 15 claim against the Director Defendants who signed the registration statement and allegedly had the power to control Rain's actions may proceed. Scienter is not required for Section 15 claims."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 35529,
      "completion_tokens": 1056,
      "total_tokens": 36585
    },
    "case_id": "cand_23_cv_03518"
  },
  {
    "model": "claude-opus",
    "model_id": "claude-opus-4-5-20251101",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "This securities class action alleges that Fastly, Inc. and its CEO Todd Nightingale and CFO Ronald Kisling violated Sections 10(b) and 20(a) of the Securities Exchange Act by making materially false and misleading statements about the company's business performance, particularly regarding macroeconomic impacts on the business, customer retention, and revenue growth from existing enterprise customers during the Class Period of November 15, 2023 to August 7, 2024. Plaintiffs allege defendants knew that revenue from large customers was declining, that macro forces were negatively impacting the business, and that the company had shifted its sales strategy away from existing customers, yet made contrary public statements.",
      "claim_rulings": [
        {
          "claim": "Section 10(b) and Rule 10b-5 violation against all Defendants",
          "ruling": "sustained",
          "scienter_analysis": "The complaint adequately pleads scienter with particularized facts creating a strong inference of intentional or reckless misconduct. First, plaintiffs allege that Nightingale personally discussed 'decreasing revenue from big customers' and that large media accounts had 'throttled down' their usage during November 2023 all hands meetings (CW1, CW6), yet publicly stated the company was not seeing macro effects that competitors were experiencing. Second, the complaint alleges weekly Customer Ops meetings tracked customer bandwidth usage with a red/yellow/green rating system, attended by senior executives and occasionally Nightingale himself (CW7), providing defendants with contemporaneous knowledge of customer traffic declines. Third, the complaint alleges defendants implemented a new sales compensation model in 2024 prioritizing new customer acquisition over existing customers (CW1, CW2, CW3, CW4), while publicly stating the company emphasized retaining and expanding existing customer relationships. Fourth, the complaint alleges defendants discontinued reporting DBNER and quarterly NRR metrics precisely when those metrics would have revealed declining existing customer growth. Fifth, the complaint alleges substantial insider stock sales by both Individual Defendants during the Class Period (Nightingale: ~$5.97 million; Kisling: ~$1.97 million). Sixth, CW5 alleges Nightingale personally knew about and directed the urgent development of a product for Apple and Amazon that had been promised in 2023 but not started until May 2024, contradicting statements about progress with large accounts. The confluence of these particularized allegations—direct knowledge from internal meetings, contemporaneous tracking systems, contradictory internal actions, suspicious timing of metric discontinuation, and insider sales—creates a strong inference of scienter that is at least as compelling as any innocent inference. Defendants' statements were not mere optimism or forward-looking projections but specific factual assertions about current business conditions that were contradicted by information defendants possessed."
        },
        {
          "claim": "Section 20(a) control person liability against Individual Defendants Nightingale and Kisling",
          "ruling": "sustained",
          "scienter_analysis": "Because the underlying Section 10(b) claim survives, the derivative Section 20(a) claim also survives. The complaint adequately alleges that the Individual Defendants, as CEO and CFO respectively, had the power to control and did control the contents of Fastly's public statements, SEC filings, press releases, and earnings calls during the Class Period. Both signed the 2023 10-K and Q1 2024 10-Q with Sarbanes-Oxley certifications. The complaint alleges they participated in earnings calls where the allegedly misleading statements were made and had authority over the company's public disclosures."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 27347,
      "completion_tokens": 808,
      "total_tokens": 28155
    },
    "case_id": "cand_24_cv_03170"
  },
  {
    "model": "claude-opus",
    "model_id": "claude-opus-4-5-20251101",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "This securities class action is brought by short sellers against Vicor Corporation and its CEO Patrizio Vinciarelli, alleging violations of Section 10(b), Rule 10b-5, and Section 20(a) of the Exchange Act. Plaintiffs claim that on July 25, 2023, defendants made false statements about having secured a 'significant' 'existing' customer for Vicor's new 4G lateral power distribution product that would ramp up in Q4 2023. Plaintiffs allege this caused the stock price to spike from $59 to over $93, forcing them to cover their short positions at a loss. Three months later, on October 24, 2023, defendants allegedly denied ever making such representations, and the stock fell to $39. Plaintiffs seek damages for their losses from covering short positions at artificially inflated prices.",
      "claim_rulings": [
        {
          "claim": "Section 10(b) and Rule 10b-5(b) against all Defendants",
          "ruling": "dismissed",
          "scienter_analysis": "The complaint fails to plead scienter with the particularity required by the PSLRA. The allegations do not establish that defendants KNEW their July 25, 2023 statements were false when made. The complaint acknowledges that Vicor's September 2024 press release stated the company had 'booked' $30 million in 'non-cancellable, non-returnable' orders from the customer, which plaintiffs dismiss as 'confound[ing] more than it explains' but do not refute. The scienter allegations are largely conclusory: (1) that Vinciarelli had access to company information is insufficient - corporate officers always have such access; (2) that Vinciarelli owned significant stock and would benefit from price increases establishes motive but not knowledge of falsity; (3) insider sales of $1 million by other directors/management in days following the announcement, while Vinciarelli himself did not sell, is insufficient to establish scienter; (4) the allegation that the deal 'fell apart' within three months does not establish defendants knew statements were false when made - this is classic 'fraud by hindsight.' The complaint presents an equally plausible innocent explanation: defendants genuinely believed they had secured a significant customer relationship that subsequently did not materialize as expected. The October 2023 statements denying prior representations, while potentially evasive, do not establish that the July 2023 statements were knowingly false. The strong inference required by the PSLRA is not met when innocent explanations are at least as compelling as the inference of fraudulent intent."
        },
        {
          "claim": "Section 20(a) Control Person Liability against Vinciarelli",
          "ruling": "dismissed",
          "scienter_analysis": "Section 20(a) claims are derivative of an underlying securities violation. Because the Court has dismissed the Section 10(b) and Rule 10b-5 claims for failure to adequately plead scienter, the Section 20(a) control person claim against Vinciarelli must also be dismissed. There can be no control person liability absent a primary violation of the securities laws."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 12903,
      "completion_tokens": 708,
      "total_tokens": 13611
    },
    "case_id": "cand_24_cv_04196"
  },
  {
    "model": "claude-opus",
    "model_id": "claude-opus-4-5-20251101",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "This is a securities class action complaint brought by Lead Plaintiffs Vinod Sodha and Amee Sodha against Robinhood Markets, Inc., certain of its officers and directors, and the underwriters of its July 2021 IPO. The complaint alleges violations of Sections 11, 12(a)(2), and 15 of the Securities Act of 1933, claiming that the Registration Statement and Prospectus contained materially false and misleading statements and omitted material information. Specifically, plaintiffs allege that Robinhood misrepresented its business strategy, claiming to prioritize customer safety and long-term interests while actually prioritizing short-term revenue through predatory practices. Plaintiffs also allege that Robinhood failed to disclose that its key performance indicators (MAU, AUC, ARPU, crypto trading volume) had been sharply declining in the months before the IPO, contradicting claims of successful growth. The complaint relies on statements from confidential witnesses (former employees) and publicly available data revealed after the IPO to support these allegations.",
      "claim_rulings": [
        {
          "claim": "Section 11 of the Securities Act (Claim One) - Against All Defendants",
          "ruling": "sustained",
          "scienter_analysis": "Section 11 claims do not require scienter. This is a strict liability claim for the issuer (Robinhood) and a negligence-based claim for other defendants (Individual Defendants and Underwriter Defendants). The complaint explicitly states this is a 'non-fraud cause of action' and that plaintiffs 'do not assert that Defendants committed intentional or reckless misconduct or that Defendants acted with scienter or fraudulent intent.' The complaint adequately alleges material misstatements and omissions in the Offering Documents regarding: (1) Robinhood's claimed business strategy of prioritizing customer safety and long-term interests; (2) the trajectory of key performance indicators, which were declining rather than growing in the months before the IPO; and (3) inadequate risk disclosures that failed to reveal risks had already materialized. The confidential witness statements provide particularized factual support for the allegation that Robinhood's stated strategy was not being followed. The post-IPO disclosures showing sharp declines in MAU, crypto trading volume, ARPU, and AUC support the inference that these trends existed at the time of the IPO. The motion to dismiss this claim is DENIED."
        },
        {
          "claim": "Section 12(a)(2) of the Securities Act (Claim Two) - Against All Defendants",
          "ruling": "sustained",
          "scienter_analysis": "Section 12(a)(2) claims do not require scienter. Like Section 11, this is a negligence-based claim. Plaintiffs must show that the prospectus contained material misstatements or omissions and that defendants were statutory sellers. The complaint adequately alleges that defendants promoted, solicited, and sold Robinhood shares through a defective Prospectus containing untrue statements of material fact and omissions. The same factual allegations supporting the Section 11 claim support this claim. Defendants had a duty to conduct reasonable investigation and, in the exercise of reasonable care, should have known of the misstatements and omissions. The motion to dismiss this claim is DENIED."
        },
        {
          "claim": "Section 15 of the Securities Act (Claim Three) - Against Individual Defendants",
          "ruling": "sustained",
          "scienter_analysis": "Section 15 is a control person liability provision that does not require independent scienter. It requires plaintiffs to allege (1) a primary violation of Section 11 or 12, and (2) that the defendant was a controlling person of the primary violator. The complaint adequately alleges that the Individual Defendants were controlling persons of Robinhood by virtue of their ownership interests, senior management positions, and/or directorships. The complaint specifically alleges that each Individual Defendant signed the Registration Statement. Because the underlying Section 11 claim survives, and the complaint adequately alleges control, this derivative claim also survives. The motion to dismiss this claim is DENIED."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 33505,
      "completion_tokens": 976,
      "total_tokens": 34481
    },
    "case_id": "cand_3_21-cv-09767"
  },
  {
    "model": "claude-opus",
    "model_id": "claude-opus-4-5-20251101",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "This securities class action alleges that SunPower Corporation and its executives violated Sections 10(b) and 20(a) of the Exchange Act by making false and misleading statements about the company's commercial business performance, financial guidance, and product quality risks during the Class Period from August 3, 2021 through January 20, 2022. Plaintiffs claim defendants knew or deliberately disregarded that cracking defects had already developed in third-party connectors across nearly all of the company's commercial solar systems, which would require tens of millions in replacement costs and prevent the company from meeting its financial guidance.",
      "claim_rulings": [
        {
          "claim": "Section 10(b) and Rule 10b-5 against all Defendants",
          "ruling": "dismissed",
          "scienter_analysis": "The complaint fails to plead particularized facts establishing a strong inference of scienter as required by the PSLRA. The allegations that defendants 'knew or deliberately disregarded' the connector cracking issue are conclusory and lack specific factual support. The complaint does not identify any confidential witnesses, internal documents, or other particularized facts demonstrating that the Individual Defendants actually knew about the cracking defects at the time they made the challenged statements. The allegation that the defects 'must have' been discovered during CIS sale due diligence is speculation, not a particularized fact. The analysts' reports suggesting the issue 'likely came up in due diligence' are third-party speculation insufficient to establish scienter. The December 2021 manual update warning about connector cracking, while potentially suggestive, does not establish that defendants knew of pervasive existing defects when making earlier statements. The complaint essentially alleges fraud by hindsight - that because the company later discovered and disclosed the defects, defendants must have known earlier. An equally plausible innocent inference is that defendants genuinely did not discover the scope of the cracking issue until the product quality assessment referenced in the January 2022 disclosure. The risk factor disclosures warning that defects 'might' occur are standard forward-looking cautionary language, not actionable misstatements. Without particularized facts showing defendants' actual contemporaneous knowledge of the defects, the complaint fails to meet the PSLRA's heightened pleading standard."
        },
        {
          "claim": "Section 20(a) control person liability against all Defendants",
          "ruling": "dismissed",
          "scienter_analysis": "Section 20(a) claims are derivative of an underlying Section 10(b) violation. Because the Section 10(b) and Rule 10b-5 claims are dismissed for failure to adequately plead scienter, the Section 20(a) claims must also be dismissed as there is no predicate securities violation upon which control person liability can be based."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 22748,
      "completion_tokens": 621,
      "total_tokens": 23369
    },
    "case_id": "cand_3_22-cv-00956"
  },
  {
    "model": "claude-opus",
    "model_id": "claude-opus-4-5-20251101",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "This is a securities class action against ImmunityBio, Inc. and individual defendants (Patrick Soon-Shiong, Richard Adcock, and David Sachs) alleging violations of Section 10(b) and Rule 10b-5 of the Securities Exchange Act, as well as Section 20(a) control person liability. Plaintiffs allege defendants made materially false and misleading statements about the company's cGMP (current good manufacturing practices) compliance at a third-party contract manufacturing organization (AGC) that manufactured Anktiva, the company's lead product candidate. The complaint alleges defendants knew of serious and recurring cGMP failures at AGC throughout the Class Period (March 10, 2021 to May 10, 2023), yet continued to represent that manufacturing resources were cGMP-compliant. The FDA ultimately rejected the Anktiva BLA due to deficiencies observed during pre-license inspections, causing a 55% stock price decline.",
      "claim_rulings": [
        {
          "claim": "Section 10(b) and Rule 10b-5 claims against all Defendants",
          "ruling": "sustained",
          "scienter_analysis": "The complaint adequately pleads scienter with particularized facts supporting a strong inference that defendants knew their statements were false when made. Key facts establishing scienter include: (1) Confidential witnesses confirm that CEO Adcock and COO Sender met monthly/bi-monthly with AGC executives throughout the Class Period specifically to discuss AGC's continued delays in batch dispositions and deviation closeouts; (2) CW3 confirms defendants became 'very concerned' and 'nervous' upon learning of the intensive FDA inspection scope; (3) Defendants Adcock and Sender were 'intricately involved' in planning, executing, and reviewing results of a mock inspection in January 2023 that revealed ongoing cGMP deficiencies; (4) After the first day of the FDA inspection revealed numerous deficiencies, Defendant Soon-Shiong demanded daily executive-to-executive calls and Defendant Adcock flew overnight to attend the inspection personally; (5) CW4 confirmed Soon-Shiong 'personally reviewed' and 'approved' the Anktiva BLA before filing, which would have required knowledge of missed stability checks and failed batch runs; (6) ImmunityBio's Quality Agreement with AGC required reporting of deviations, FDA inspection observations, and batch records, and CW3 confirmed ImmunityBio was '100 percent' aware of missed batch disposition deadlines; (7) The company initiated plans to manufacture Anktiva in-house mid-Class Period, suggesting dissatisfaction with AGC's services; (8) Anktiva was critical to the company's success as its lead product candidate with no other approved drugs, heightening the inference that defendants closely monitored its manufacturing. The complaint goes beyond conclusory allegations to provide specific facts about what defendants knew, when they knew it, and how they obtained that knowledge through regular meetings, reporting mechanisms, and direct involvement in inspection preparation and monitoring."
        },
        {
          "claim": "Section 20(a) control person liability claims against Individual Defendants (Soon-Shiong, Adcock, and Sachs)",
          "ruling": "sustained",
          "scienter_analysis": "Because the underlying Section 10(b) and Rule 10b-5 claims are sustained, the derivative Section 20(a) claims also survive. The complaint adequately alleges that the Individual Defendants had direct and supervisory involvement in ImmunityBio's day-to-day operations and exercised control over the company's public statements. Defendant Soon-Shiong served as Executive Chairman and Global Chief Scientific and Medical Officer, and CW3 described him as an 'extreme control freak' who was 'calling the shots' and issuing orders to CEO Adcock. Defendant Adcock served as CEO and was directly involved in AGC meetings and inspection preparation. Defendant Sachs served as CFO and signed multiple SEC filings. All Individual Defendants signed the annual reports and other SEC filings containing the alleged misstatements."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 37763,
      "completion_tokens": 920,
      "total_tokens": 38683
    },
    "case_id": "casd_3_23-cv-01216"
  },
  {
    "model": "claude-opus",
    "model_id": "claude-opus-4-5-20251101",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "This is an SEC enforcement action, not a private securities class action, against Lovesac, its former CFO Donna Dellomo, and former Controller Yoon Um for alleged accounting fraud involving $2.2 million in last mile shipping expenses. The complaint alleges that Dellomo and Um devised a scheme to improperly capitalize shipping expenses to avoid missing gross margin projections and to avoid restating prior financial statements. The complaint contains detailed factual allegations including specific dates, internal communications (Microsoft Teams chats and emails), and the mechanics of the fraudulent journal entry. Because this is an SEC enforcement action rather than a private securities class action, the PSLRA's heightened pleading standards do not apply. The SEC need only meet the standard pleading requirements of Rule 8 and Rule 9(b) for fraud claims.",
      "claim_rulings": [
        {
          "claim": "First Claim - Securities Act Sections 17(a)(1) and (3) against Dellomo and Um",
          "ruling": "sustained",
          "scienter_analysis": "The complaint adequately alleges scienter through particularized facts: (1) Um's own statements that she could not justify the accounting treatment and did not feel comfortable with it, yet proceeded anyway; (2) Dellomo and Um's knowledge as CPAs that capitalizing outbound shipping expenses violated GAAP; (3) specific communications showing awareness that the journal entry was designed to meet gross margin targets; (4) Um's statement hoping the entry would 'do the trick' for meeting targets; (5) the absence of any documented materiality analysis or accounting support contrary to normal practice. These facts establish knowing or reckless conduct."
        },
        {
          "claim": "Second Claim - Securities Act Section 17(a)(3) against Lovesac",
          "ruling": "sustained",
          "scienter_analysis": "Section 17(a)(3) requires only negligence, not scienter. The complaint adequately alleges that Lovesac engaged in transactions and practices that operated as a fraud through its failure to maintain adequate internal controls and the resulting materially false financial statements."
        },
        {
          "claim": "Third Claim - Exchange Act Section 10(b) and Rules 10b-5(a) and (c) against Dellomo and Um",
          "ruling": "sustained",
          "scienter_analysis": "The complaint pleads scienter with particularity through: (1) contemporaneous Microsoft Teams communications showing Um knew the accounting was improper ('I don't know how to tell [Dellomo] I don't feel comfortable with it'); (2) Um's statement that she could not 'justify' reversing the expenses and another employee's warning it would be 'a giant black eye for the auditors'; (3) Dellomo's approval of the journal entry without the supporting documentation she typically required; (4) both defendants' CPA credentials and experience establishing they knew capitalizing shipping expenses violated GAAP; (5) the direct connection between the scheme and meeting publicly disclosed gross margin projections. These particularized facts create a strong inference of fraudulent intent."
        },
        {
          "claim": "Fourth Claim - Exchange Act Section 10(b) and Rule 10b-5(b) against Dellomo",
          "ruling": "sustained",
          "scienter_analysis": "The complaint adequately alleges Dellomo knowingly made false statements through: (1) her false certification of the Q1 2024 Form 10-Q; (2) her false management representation letter to auditors; (3) her failure to disclose the improper journal entry to auditors when directly asked about unusual transactions; (4) her approval of Um's journal entry without required documentation; (5) her awareness of the $2.2 million discrepancy and its impact on gross margin from the April 23, 2023 email she authored. These facts establish she knew the statements were false when made."
        },
        {
          "claim": "Fifth Claim - Aiding and Abetting Dellomo's Section 10(b) violations against Um",
          "ruling": "sustained",
          "scienter_analysis": "The complaint adequately alleges Um knowingly provided substantial assistance to Dellomo's violations through: (1) creating and booking the improper journal entry; (2) her own communications acknowledging she could not justify the accounting treatment; (3) her statement hoping the entry would 'do the trick'; (4) her CPA knowledge that the capitalization violated GAAP. The particularized allegations of her knowing participation in the scheme support this claim."
        },
        {
          "claim": "Sixth Claim - Exchange Act Section 13(b)(5) against Dellomo",
          "ruling": "sustained",
          "scienter_analysis": "The complaint alleges Dellomo knowingly circumvented internal controls and falsified books through specific facts: approving the improper journal entry without required documentation, failing to implement adequate accrual procedures, and concealing the scheme from auditors. Her role as CFO and CPA, combined with her direct involvement in the scheme, supports the knowing violation."
        },
        {
          "claim": "Seventh Claim - Exchange Act Rule 13b2-1 against Dellomo and Um",
          "ruling": "sustained",
          "scienter_analysis": "Rule 13b2-1 does not require scienter; it prohibits directly or indirectly falsifying books and records. The complaint adequately alleges both defendants falsified Lovesac's books through the improper journal entry capitalizing the shipping expenses."
        },
        {
          "claim": "Eighth Claim - Exchange Act Rule 13b2-2 against Dellomo",
          "ruling": "sustained",
          "scienter_analysis": "The complaint adequately alleges Dellomo made material omissions to auditors through: (1) signing a false management representation letter with specific false statements enumerated; (2) failing to disclose the improper journal entry when asked about unusual transactions; (3) her knowledge of the scheme and obligation to disclose it. These particularized facts support the claim."
        },
        {
          "claim": "Ninth Claim - Exchange Act Section 13(a) and Rules 12b-20, 13a-1, 13a-11, 13a-13 against Lovesac",
          "ruling": "sustained",
          "scienter_analysis": "These reporting violations do not require scienter. The complaint adequately alleges Lovesac filed materially false and misleading reports (Forms 10-K, 10-Q, and 8-K) that failed to properly account for shipping expenses and failed to disclose material weaknesses in internal controls."
        },
        {
          "claim": "Tenth Claim - Aiding and Abetting Lovesac's Section 13(a) violations against Dellomo and Um",
          "ruling": "sustained",
          "scienter_analysis": "The complaint adequately alleges both defendants knowingly provided substantial assistance to Lovesac's reporting violations through their creation and approval of the improper journal entry that rendered the company's SEC filings false and misleading. Their contemporaneous communications and CPA expertise establish the requisite knowledge."
        },
        {
          "claim": "Eleventh Claim - Exchange Act Rule 13a-14 against Dellomo",
          "ruling": "sustained",
          "scienter_analysis": "The complaint adequately alleges Dellomo falsely certified the Q1 2024 Form 10-Q while knowing it contained material misstatements and omissions regarding the shipping expenses and internal control weaknesses. Her direct involvement in the scheme establishes knowledge of the falsity."
        },
        {
          "claim": "Twelfth Claim - Exchange Act Section 13(b)(2)(A) against Lovesac",
          "ruling": "sustained",
          "scienter_analysis": "Section 13(b)(2)(A) is a strict liability provision not requiring scienter. The complaint adequately alleges Lovesac failed to keep accurate books and records by improperly recording the $2.2 million shipping expenses."
        },
        {
          "claim": "Thirteenth Claim - Aiding and Abetting Lovesac's Section 13(b)(2)(A) violations against Dellomo and Um",
          "ruling": "sustained",
          "scienter_analysis": "The complaint adequately alleges both defendants knowingly assisted Lovesac's books and records violations through their creation and approval of the improper journal entry. Their communications and CPA expertise establish they knew the entries were inaccurate."
        },
        {
          "claim": "Fourteenth Claim - Exchange Act Section 13(b)(2)(B) against Lovesac",
          "ruling": "sustained",
          "scienter_analysis": "Section 13(b)(2)(B) is a strict liability provision not requiring scienter. The complaint adequately alleges Lovesac failed to maintain adequate internal accounting controls, as evidenced by the flawed accrual methodology and the ability of officers to book improper journal entries without adequate oversight."
        },
        {
          "claim": "Fifteenth Claim - Aiding and Abetting Lovesac's Section 13(b)(2)(B) violations against Dellomo",
          "ruling": "sustained",
          "scienter_analysis": "The complaint adequately alleges Dellomo, as CFO responsible for internal controls, knowingly failed to implement adequate controls and knowingly assisted Lovesac's violations. Her direct involvement in the scheme and her role overseeing the finance and accounting group establish the requisite knowledge."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 13725,
      "completion_tokens": 2262,
      "total_tokens": 15987
    },
    "case_id": "ctd-3_24-cv-01727"
  },
  {
    "model": "claude-opus",
    "model_id": "claude-opus-4-5-20251101",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "This is an SEC enforcement action against Binance Holdings Limited, BAM Trading Services Inc., BAM Management US Holdings Inc., and Changpeng Zhao alleging violations of federal securities laws including operating unregistered exchanges, broker-dealers, and clearing agencies, unregistered offers and sales of securities (BNB, BUSD, BNB Vault, Simple Earn, and staking programs), and fraud claims under Section 17(a)(2) and (3) of the Securities Act. The complaint alleges defendants operated crypto asset trading platforms serving U.S. investors without proper registration, engaged in wash trading, made false statements about trade surveillance, and commingled customer funds.",
      "claim_rulings": [
        {
          "claim": "First Claim - Securities Act Sections 5(a) and 5(c) (Unregistered Offers and Sales of BNB against Binance)",
          "ruling": "sustained",
          "scienter_analysis": "Not applicable. Section 5 claims are strict liability violations that do not require scienter. The complaint adequately alleges that Binance offered and sold BNB without a registration statement in effect, using means of interstate commerce, and that BNB constitutes an investment contract/security under Howey based on the detailed allegations regarding the ICO, whitepaper representations, profit expectations tied to platform success, and ongoing promotional efforts."
        },
        {
          "claim": "Second Claim - Securities Act Sections 5(a) and 5(c) (Unregistered Offers and Sales of BUSD against Binance)",
          "ruling": "sustained",
          "scienter_analysis": "Not applicable. Section 5 claims are strict liability violations that do not require scienter. The complaint adequately alleges that Binance offered and sold BUSD as part of a profit-earning scheme, marketing various APYs and profit opportunities, pooling proceeds in reserves, and earning returns on those pooled assets, satisfying the Howey test for investment contracts."
        },
        {
          "claim": "Third Claim - Securities Act Sections 5(a) and 5(c) (Unregistered Offers and Sales of Simple Earn and BNB Vault against Binance)",
          "ruling": "sustained",
          "scienter_analysis": "Not applicable. Section 5 claims are strict liability violations that do not require scienter. The complaint adequately alleges these programs were offered as profit-making opportunities where Binance pooled investor crypto assets, used managerial expertise to deploy them, and generated revenue to pay returns to investors, constituting investment contracts."
        },
        {
          "claim": "Fourth Claim - Securities Act Sections 5(a) and 5(c) (Unregistered Offers and Sales of Staking Program against BAM Trading)",
          "ruling": "sustained",
          "scienter_analysis": "Not applicable. Section 5 claims are strict liability violations that do not require scienter. The complaint adequately alleges BAM Trading's staking program involved investment of crypto assets, pooling in common staking pools, with reasonable expectations of profits derived from BAM Trading's efforts in validating transactions, constituting an investment contract."
        },
        {
          "claim": "Fifth Claim - Exchange Act Section 5 (Failure to Register as Exchange for Binance.com Platform against Binance)",
          "ruling": "sustained",
          "scienter_analysis": "Not applicable. Exchange Act Section 5 violations do not require scienter. The complaint adequately alleges Binance operated a marketplace bringing together multiple buyers and sellers of securities using established, non-discretionary methods (MatchBox matching engine), meeting the definition of an exchange under Section 3(a)(1) and Rule 3b-16(a)."
        },
        {
          "claim": "Sixth Claim - Exchange Act Section 15(a) (Failure to Register as Broker-Dealer for Binance.com Platform against Binance)",
          "ruling": "sustained",
          "scienter_analysis": "Not applicable. Exchange Act Section 15(a) violations do not require scienter. The complaint adequately alleges Binance engaged in the business of effecting transactions in securities for others (broker) and buying/selling securities for its own account through Binance OTC (dealer) without registration."
        },
        {
          "claim": "Seventh Claim - Exchange Act Section 17A(b) (Failure to Register as Clearing Agency for Binance.com Platform against Binance)",
          "ruling": "sustained",
          "scienter_analysis": "Not applicable. Exchange Act Section 17A(b) violations do not require scienter. The complaint adequately alleges Binance acted as intermediary in making payments and deliveries in securities transactions, maintained custody of securities in omnibus wallets, and settled transactions by debiting/crediting internal ledgers."
        },
        {
          "claim": "Eighth Claim - Exchange Act Section 5 (Failure to Register as Exchange for Binance.US Platform against Binance and BAM Trading)",
          "ruling": "sustained",
          "scienter_analysis": "Not applicable. Exchange Act Section 5 violations do not require scienter. The complaint adequately alleges Binance and BAM Trading, acting as a group of persons, operated the Binance.US Platform as an exchange bringing together multiple buyers and sellers using non-discretionary matching rules."
        },
        {
          "claim": "Ninth Claim - Exchange Act Section 15(a) (Failure to Register as Broker for Binance.US Platform against BAM Trading)",
          "ruling": "sustained",
          "scienter_analysis": "Not applicable. Exchange Act Section 15(a) violations do not require scienter. The complaint adequately alleges BAM Trading engaged in the business of effecting securities transactions for others, soliciting investors, handling customer funds and crypto assets, and receiving transaction fee compensation."
        },
        {
          "claim": "Tenth Claim - Exchange Act Section 17A(b) (Failure to Register as Clearing Agency for Binance.US Platform against Binance and BAM Trading)",
          "ruling": "sustained",
          "scienter_analysis": "Not applicable. Exchange Act Section 17A(b) violations do not require scienter. The complaint adequately alleges both defendants acted as intermediaries in settling transactions, maintained custody of customer crypto assets, and facilitated settlement by debiting/crediting internal ledgers."
        },
        {
          "claim": "Eleventh Claim - Exchange Act Sections 5, 15(a), and 17A(b) via Section 20(a) Control Person Liability (Against Zhao for Binance.com Platform)",
          "ruling": "sustained",
          "scienter_analysis": "Not applicable. The underlying Exchange Act Sections 5, 15(a), and 17A(b) violations do not require scienter. Section 20(a) control person liability is derivative of the underlying violations, which are adequately alleged. The complaint sufficiently alleges Zhao's control over Binance as founder, beneficial owner, and CEO who directed all aspects of Binance's business operations."
        },
        {
          "claim": "Twelfth Claim - Exchange Act Sections 5, 15(a), and 17A(b) via Section 20(a) Control Person Liability (Against Zhao for Binance.US Platform)",
          "ruling": "sustained",
          "scienter_analysis": "Not applicable. The underlying Exchange Act violations do not require scienter. Section 20(a) control person liability is derivative of the underlying violations, which are adequately alleged. The complaint sufficiently alleges Zhao's control over both Binance and BAM Trading, including his role as Chairman of BAM Trading's Board, his control over bank accounts, approval authority over expenditures, and direction of key business decisions."
        },
        {
          "claim": "Thirteenth Claim - Securities Act Sections 17(a)(2) and (3) (Against BAM Management and BAM Trading)",
          "ruling": "sustained",
          "scienter_analysis": "Sections 17(a)(2) and (3) of the Securities Act require only negligence, not scienter. The complaint adequately alleges that BAM Trading and BAM Management made materially false and misleading statements about trade surveillance and manipulative trading controls on the Binance.US Platform, and engaged in practices that operated as a fraud on purchasers. Specific allegations include: (1) public statements touting 'on-chain analytics' and 'risk parameters' to prevent toxic behavior when no such controls existed; (2) representations in the Pitch Deck about 'robust trade surveillance' using Trade Surveillance Company A when such surveillance was not implemented until February 2022 at earliest; (3) reporting trading volumes without disclosing extensive wash trading by Sigma Chain, a Zhao-controlled entity; (4) internal knowledge that 'market manipulation controls have not been established' and no monitoring for wash trading existed. These particularized allegations of false statements and deceptive conduct satisfy the negligence standard for Section 17(a)(2) and (3) claims."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 58659,
      "completion_tokens": 2136,
      "total_tokens": 60795
    },
    "case_id": "dcd-1_23-cv-01599"
  },
  {
    "model": "claude-opus",
    "model_id": "claude-opus-4-5-20251101",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "This securities class action alleges that Danaher Corporation and its executives made materially false and misleading statements about the company's bioprocessing business prospects during the Class Period (January 27, 2022 to October 23, 2023). Plaintiffs claim defendants repeatedly issued overly optimistic forecasts for COVID-related and non-COVID bioprocessing revenues while knowing that: (1) COVID-related vaccine and therapeutic demand was declining faster than disclosed; (2) large pharmaceutical customers were stockpiling inventory rather than placing new orders; and (3) smaller biotech customers faced funding constraints that reduced demand. The complaint alleges defendants made piecemeal downward revisions to guidance over seven quarters, with each disclosure causing stock price drops.",
      "claim_rulings": [
        {
          "claim": "Section 10(b) and Rule 10b-5 against all Defendants",
          "ruling": "dismissed",
          "scienter_analysis": "The complaint fails to plead particularized facts establishing a strong inference of scienter. The allegations primarily constitute 'fraud by hindsight' - defendants made optimistic forecasts that proved incorrect as market conditions deteriorated. Key deficiencies include: (1) The confidential witness allegations are weak - CW4's claim that Blair said he 'made up' projections is vague hearsay without context about what specifically was fabricated or why it was fraudulent rather than optimistic; (2) CW1-CW3 worked in unrelated business segments (water quality/EAS) and provide no particularized facts about bioprocessing knowledge; (3) The complaint acknowledges defendants repeatedly disclosed challenges and revised guidance downward throughout the Class Period, which is inconsistent with fraudulent concealment; (4) Defendants' statements about customer relationships and market monitoring are consistent with legitimate business optimism rather than fraud; (5) Stock sales by Blair and McGrew, while suspicious in timing, were partially pursuant to Rule 10b5-1 plans and compensation arrangements, and the amounts are not dramatically out of pattern; (6) The 'core operations' inference is insufficient where the complaint shows defendants were actively communicating with customers and adjusting forecasts based on new information; (7) Innocent explanations - that defendants genuinely believed non-COVID growth would offset COVID declines based on customer feedback - are at least as compelling as fraudulent intent. The gradual downward revisions suggest defendants were learning of deteriorating conditions over time rather than concealing known facts."
        },
        {
          "claim": "Section 20(a) Control Person Liability against Blair and McGrew",
          "ruling": "dismissed",
          "scienter_analysis": "Section 20(a) claims are derivative of the underlying Section 10(b) violation. Because the Court dismisses the primary Section 10(b) claim for failure to adequately plead scienter, the Section 20(a) control person claims against Defendants Blair and McGrew must also be dismissed. There can be no control person liability absent an underlying securities violation."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 40158,
      "completion_tokens": 657,
      "total_tokens": 40815
    },
    "case_id": "dcd-1_23-cv-02055"
  },
  {
    "model": "claude-opus",
    "model_id": "claude-opus-4-5-20251101",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "This securities class action complaint alleges that Focus Financial Partners and its officers and directors made materially false and misleading statements in connection with the company's $7 billion merger with Clayton, Dubilier & Rice (CD&R). Plaintiffs claim that defendants favored CD&R over a higher bidder, concealed conflicts of interest among Special Committee members, and issued a misleading proxy statement to secure shareholder approval of the merger at an unfair price of $53 per share when another bidder offered $55 per share.",
      "claim_rulings": [
        {
          "claim": "Section 10(b) and Rule 10b-5 claims against all defendants",
          "ruling": "dismissed",
          "scienter_analysis": "The complaint fails to plead particularized facts establishing a strong inference of scienter. The allegations amount to fraud by hindsight - plaintiffs allege defendants favored CD&R and made misleading statements, but do not provide specific facts showing defendants actually knew their statements were false when made. The complaint relies heavily on: (1) the existence of conflicts of interest, which alone does not establish fraudulent intent; (2) the fact that a higher bid existed, which does not prove defendants knew their statements about the process being 'fair' were false; (3) conclusory allegations that defendants 'knew or recklessly disregarded' the truth. The alleged motives (TRA payments, management retention, equity rollovers) are equally consistent with legitimate business interests as with fraud. Directors and officers commonly have financial interests in transactions they approve; this does not establish they knew their public statements were false. The complaint's scienter allegations in paragraphs 218-227 are largely conclusory, stating defendants 'knew' facts without particularized allegations of how, when, or from whom they obtained such knowledge. The inference that defendants acted with innocent business judgment is at least as compelling as the inference of fraudulent intent."
        },
        {
          "claim": "Section 14(a) and Rule 14a-9 claims against Focus, Special Committee Defendants, Board Defendants, and Officer Defendants",
          "ruling": "sustained",
          "scienter_analysis": "Section 14(a) claims do not require scienter; negligence is sufficient. Plaintiffs have adequately alleged material misstatements and omissions in the Proxy, including: (1) representations that Special Committee members were 'independent and disinterested' when they stood to receive substantial payments from the merger; (2) omission of the last-minute compensation increases for Special Committee members approved moments before they voted for the merger; (3) omission of personal and business relationships between Special Committee members and defendants Adolf, CD&R, and Stone Point; (4) misrepresentations about the adequacy of the sale process and outreach to strategic acquirers; (5) omission of Goldman Sachs' conflicts from its concurrent representation in the NKSFB sale process. These allegations are sufficient to state a claim for negligent misrepresentation under Section 14(a)."
        },
        {
          "claim": "Section 20(a) control person liability claims against Special Committee Defendants, Board Defendants, and Officer Defendants",
          "ruling": "dismissed",
          "scienter_analysis": "Section 20(a) claims are derivative of underlying securities violations. To the extent the Section 20(a) claims are predicated on the Section 10(b) violation, they must be dismissed because the underlying Section 10(b) claim fails for lack of adequately pleaded scienter. However, to the extent the Section 20(a) claims are predicated on the Section 14(a) violation, they may proceed, as plaintiffs have adequately alleged that these defendants controlled Focus and were culpable participants in the Section 14(a) violations through their direct involvement in preparing, reviewing, and disseminating the Proxy."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 38083,
      "completion_tokens": 843,
      "total_tokens": 38926
    },
    "case_id": "dde_ 23_cv_1466"
  },
  {
    "model": "claude-opus",
    "model_id": "claude-opus-4-5-20251101",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "This securities class action alleges that Walmart and its executives (McMillon and Biggs) violated Section 10(b) and Rule 10b-5 of the Exchange Act by concealing government investigations into Walmart's violations of the Controlled Substances Act related to opioid dispensing and distribution practices. Plaintiffs allege defendants failed to disclose criminal and civil DOJ investigations, violated GAAP and SEC disclosure requirements, made false statements about Walmart's opioid compliance efforts, and misrepresented risk factors as hypothetical when they had already materialized. The complaint also asserts Section 20(a) control person liability against the Individual Defendants.",
      "claim_rulings": [
        {
          "claim": "Section 10(b) and Rule 10b-5 - False statements regarding disclosure of all reasonably possible material liabilities",
          "ruling": "sustained",
          "scienter_analysis": "The complaint adequately pleads scienter with particularized facts. The June 2014 Portfolio Scoring Worksheet explicitly states the Board was 'informed' that Walmart had 'no processes in place' for suspicious order monitoring, that severe financial and reputational harm was 'likely,' and this was related to a 'settlement agreement with a Government Agency' (the 2011 MOA). The Individual Defendants were members of the Ethics, Compliance and Risk Committee that received these documents. McMillon personally approved presentations to DOJ prosecutors in July 2018 regarding the threatened indictment, demonstrating actual knowledge of the criminal investigation. The complaint alleges specific internal documents showing defendants knew of CSA violations and investigation risks yet certified financial statements as accurate. These particularized facts support a strong inference of knowing or reckless conduct, not mere corporate mismanagement."
        },
        {
          "claim": "Section 10(b) and Rule 10b-5 - False statements portraying Walmart as 'opioid steward' with comprehensive compliance policies",
          "ruling": "sustained",
          "scienter_analysis": "The complaint pleads particularized facts showing defendants knew these statements were false when made. Internal documents show Walmart's compliance director Brad Nelson stated 'driving sales and patient awareness is a far better use of our Market Directors and Market Manager's time' rather than compliance. The complaint details specific instances where pharmacists were prohibited from refusing prescriptions from known pill-mill prescribers, internal surveys showing pharmacists felt pressured to fill prescriptions unsafely, and bonus structures incentivizing prescription volume regardless of legitimacy. The October 2017 press release claiming 'comprehensive policies and training' was issued while defendants knew of the ongoing criminal investigation and internal compliance failures documented since at least 2014. The contemporaneous issuance of 'stewardship' statements while concealing investigations supports a strong inference of intent to deceive."
        },
        {
          "claim": "Section 10(b) and Rule 10b-5 - False risk disclosures presenting materialized risks as hypothetical",
          "ruling": "sustained",
          "scienter_analysis": "Particularized facts support scienter. By March 2017, defendants knew of the criminal investigation that began December 2016 following the DEA raid. By March 2018, defendants knew prosecutors intended to indict Walmart. The 2014 PSW and 2015 Compliance Proposal explicitly acknowledged Walmart faced 'severe' risks of DEA enforcement due to non-compliance. Yet risk disclosures continued to present regulatory enforcement as hypothetical future possibilities rather than disclosing the actual ongoing investigations. The complaint alleges McMillon and Biggs, as Ethics, Compliance and Risk Committee members, had direct access to documents showing these risks had materialized. Presenting known, materialized risks as hypothetical future possibilities while possessing specific knowledge of actual investigations creates a strong inference of scienter."
        },
        {
          "claim": "Section 10(b) and Rule 10b-5 - False SOX Certifications",
          "ruling": "sustained",
          "scienter_analysis": "The complaint pleads particularized facts that McMillon and Biggs knew the certifications were false. Both defendants were Ethics, Compliance and Risk Committee members with access to internal compliance documents. McMillon personally approved DOJ presentation materials and was consulted during formulation of Walmart's response to the criminal investigation. The certifications attested that financial statements fairly presented the company's condition and that no fraud involving management existed, yet defendants allegedly knew of undisclosed material loss contingencies from the investigations and knew of the company's systematic CSA violations. The specific allegations of McMillon's personal involvement in responding to the threatened indictment and both defendants' committee memberships providing access to compliance failure documentation support a strong inference that they knew the certifications were false."
        },
        {
          "claim": "Section 20(a) Control Person Liability against Individual Defendants",
          "ruling": "sustained",
          "scienter_analysis": "Because the underlying Section 10(b) claims are sustained, the Section 20(a) derivative claims may proceed. The complaint adequately alleges that McMillon (CEO) and Biggs (CFO) were controlling persons who participated in the operation and management of Walmart, signed all SEC filings during the Class Period, served on the Ethics, Compliance and Risk Committee, and had the power to cause the company to make the alleged misstatements. McMillon's direct involvement in the DOJ investigation response and both defendants' positions as senior officers who signed the challenged SEC filings support control person status."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 51209,
      "completion_tokens": 1190,
      "total_tokens": 52399
    },
    "case_id": "dde_21_cv_55"
  },
  {
    "model": "claude-opus",
    "model_id": "claude-opus-4-5-20251101",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "This securities class action involves allegations that Defendants CFT Solutions, FxWinning, and individual executives operated a fraudulent forex trading scheme, inducing Plaintiffs to invest over $27 million based on false representations about proprietary trading algorithms, high returns, and fund security. Plaintiffs allege Defendants prevented withdrawals beginning in early 2023 under the guise of KYC/AML compliance procedures, while Individual Defendants allegedly withdrew funds for personal benefit. The complaint asserts claims under federal securities laws, the Commodity Exchange Act, Florida securities laws, and various state common law theories.",
      "claim_rulings": [
        {
          "claim": "Count I - Violation of Securities Act of 1933, 15 U.S.C. § 77e and 77l(a)(1) (against CFT and FxWinning)",
          "ruling": "sustained",
          "scienter_analysis": "Section 12(a)(1) claims for unregistered securities do not require scienter. The complaint adequately alleges that the investment accounts constitute securities under the Howey test (investment of money in a common enterprise with expectation of profits derived from efforts of others), that Defendants offered and sold these securities, and that no registration statement was filed. Plaintiffs have stated a claim for strict liability under Section 12(a)(1)."
        },
        {
          "claim": "Count II - Violation of Securities Exchange Act Section 10(b) and Rule 10b-5 (against CFT, FxWinning, de Rocha, Cardenas, and Brito Cutie)",
          "ruling": "dismissed",
          "scienter_analysis": "The complaint fails to plead scienter with the particularity required by the PSLRA. While Plaintiffs allege numerous misrepresentations about trading returns, platform capabilities, and fund security, the scienter allegations are largely conclusory. Allegations that statements 'were either knowingly false or should have been known to have been false' are insufficient under Tellabs. The complaint relies heavily on 'upon information and belief' allegations without stating the factual basis for such belief. The allegation that Defendants 'knew or should have known' the scheme was fraudulent 'since the beginning' is classic fraud-by-hindsight reasoning. While the complaint alleges Individual Defendants received commissions and purchased real property, it does not establish with particularity that specific defendants knew their statements were false at the time made. The failure to process withdrawals and subsequent business collapse, while suspicious, does not by itself create a strong inference of scienter at the time the original representations were made. Innocent explanations—including legitimate business difficulties, liquidity provider issues, or negligent mismanagement—are at least as plausible as intentional fraud based on the particularized facts alleged."
        },
        {
          "claim": "Count III - Violation of Commodity Exchange Act, 7 U.S.C. §§ 6b, 6e, 6o, and 25 (against CFT, FxWinning, de Rocha, Cardenas, and Brito Cutie)",
          "ruling": "sustained",
          "scienter_analysis": "The CEA claims are pleaded in the alternative to the securities claims. The complaint adequately alleges fraud in connection with commodity transactions, including false statements about trading capabilities and returns, failure to register as required, and operation of a commodity pool. The CEA fraud provisions have different pleading requirements than the PSLRA, and the complaint sufficiently alleges the elements of CEA violations."
        },
        {
          "claim": "Count IV - Violation of Florida Securities and Investor Protection Act, Sections 517.301 and 517.211 (against CFT, FxWinning, de Rocha, Cardenas, and Brito Cutie)",
          "ruling": "sustained",
          "scienter_analysis": "Florida's securities fraud statute does not require the heightened PSLRA scienter pleading standard. The complaint adequately alleges material misrepresentations and omissions in connection with the sale of securities under Florida law, including false statements about trading returns, platform capabilities, and fund security."
        },
        {
          "claim": "Count V - Breach of Contract (against FxWinning)",
          "ruling": "sustained",
          "scienter_analysis": "Not applicable. Breach of contract does not require scienter. The complaint adequately alleges the existence of a contract (terms and conditions), Plaintiffs' performance, FxWinning's breach by refusing withdrawals, and resulting damages."
        },
        {
          "claim": "Count VI - Breach of Fiduciary Duty (against all Defendants)",
          "ruling": "sustained",
          "scienter_analysis": "Not applicable to scienter analysis. The complaint adequately alleges that Defendants held Plaintiffs' funds in a fiduciary capacity, owed duties of good faith and care, and breached those duties by misappropriating funds and refusing withdrawals."
        },
        {
          "claim": "Count VII - Fraud in the Inducement (against CFT, FxWinning, de Rocha, Cardenas, and Brito Cutie)",
          "ruling": "sustained",
          "scienter_analysis": "Common law fraud claims are not subject to the PSLRA's heightened pleading requirements. Under Rule 9(b), the complaint adequately alleges the who, what, when, where, and how of the alleged fraudulent inducement, including specific misrepresentations about trading capabilities, returns, and fund security made at identifiable times and places."
        },
        {
          "claim": "Count VIII - Negligent Misrepresentation (against CFT, FxWinning, de Rocha, Cardenas, and Brito Cutie)",
          "ruling": "sustained",
          "scienter_analysis": "Not applicable. Negligent misrepresentation does not require intent to deceive. The complaint adequately alleges false information was provided, Defendants failed to exercise reasonable care, Plaintiffs justifiably relied on the information, and suffered damages."
        },
        {
          "claim": "Count IX - Conversion (against all Defendants)",
          "ruling": "sustained",
          "scienter_analysis": "Not applicable. Conversion does not require scienter. The complaint adequately alleges Plaintiffs' ownership of funds, Defendants' wrongful dominion over those funds inconsistent with Plaintiffs' ownership rights, and resulting damages."
        },
        {
          "claim": "Count X - Unjust Enrichment (against all Defendants)",
          "ruling": "sustained",
          "scienter_analysis": "Not applicable. Unjust enrichment does not require scienter. The complaint adequately alleges Defendants received a benefit (Plaintiffs' funds), retention of which would be inequitable under the circumstances."
        },
        {
          "claim": "Count XI - Civil Conspiracy (against all Defendants)",
          "ruling": "sustained",
          "scienter_analysis": "The civil conspiracy claim is predicated on the underlying torts, including common law fraud and conversion, which have been adequately pleaded. The complaint alleges a common purpose among Defendants to defraud investors and specific overt acts in furtherance of that conspiracy."
        },
        {
          "claim": "Section 20(a) Control Person Liability",
          "ruling": "dismissed",
          "scienter_analysis": "Although no Section 20(a) claim is expressly pleaded, to the extent any such claim is implied, it must be dismissed. Section 20(a) liability is derivative of an underlying Section 10(b) violation. Because the Section 10(b) claim is dismissed for failure to adequately plead scienter, any Section 20(a) claim necessarily fails as well."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 18327,
      "completion_tokens": 1833,
      "total_tokens": 20160
    },
    "case_id": "flsd-1_23-cv-23139"
  },
  {
    "model": "claude-opus",
    "model_id": "claude-opus-4-5-20251101",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "This securities class action complaint alleges violations of Sections 11 and 15 of the Securities Act of 1933 in connection with GoHealth's July 2020 IPO. Lead Plaintiffs allege that the Registration Statement contained material misstatements and omissions regarding GoHealth's business model, specifically that the company had planned 2020 as an 'investment year' involving significant carrier expansion that would negatively impact the company's critical LTV/CAC metric. Plaintiffs claim the Registration Statement failed to disclose that GoHealth's rapid growth was predicated on unsustainable concentration with just two carriers (Humana and Anthem), and that planned expansion to new carriers would result in reduced commission rates, increased marketing costs, and decreased persistency. The complaint brings strict liability claims under Section 11 against GoHealth, Individual Defendants, and Underwriter Defendants, and control person liability claims under Section 15 against Individual Defendants, NVX Holdings, and Centerbridge.",
      "claim_rulings": [
        {
          "claim": "Section 11 of the Securities Act (Count I)",
          "ruling": "sustained",
          "scienter_analysis": "Section 11 claims are strict liability claims that do not require proof of scienter. The complaint explicitly states that 'Lead Plaintiffs do not claim that any of the Section 11 Defendants engaged in intentional or reckless misconduct or acted with fraudulent intent.' The PSLRA's heightened scienter pleading requirements do not apply to Section 11 claims under the Securities Act of 1933. The complaint adequately alleges that the Registration Statement contained material misstatements and omissions regarding GoHealth's planned 'investment year,' the negative impacts of carrier expansion on LTV/CAC, increased reliance on SNPs generating non-commissionable revenue, and known trends affecting persistency and churn. These allegations, if proven, could establish liability under Section 11's strict liability standard for material misstatements or omissions in a registration statement."
        },
        {
          "claim": "Section 15 of the Securities Act (Count II)",
          "ruling": "sustained",
          "scienter_analysis": "Section 15 control person liability claims under the Securities Act are derivative of Section 11 claims and similarly do not require proof of scienter. Since the underlying Section 11 claim survives, the Section 15 claims against the Individual Defendants, NVX Holdings, Centerbridge, and GoHealth may proceed. The complaint adequately alleges that these defendants possessed the power to control GoHealth's actions, including the contents of the Registration Statement. The Registration Statement itself acknowledged that the Founders and Centerbridge controlled approximately 70.8% of voting power and exercised significant influence over all matters requiring stockholder approval. GoHealth was explicitly designated as a 'controlled company' under Nasdaq rules. These allegations sufficiently plead control person status for purposes of Section 15 liability."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 27954,
      "completion_tokens": 641,
      "total_tokens": 28595
    },
    "case_id": "ilnd-1_20_cv_05593"
  },
  {
    "model": "claude-opus",
    "model_id": "claude-opus-4-5-20251101",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "This case involves DarkPulse, Inc. suing FirstFire Global Opportunities Fund, LLC and Eli Fireman, alleging that FirstFire operated as an unregistered securities dealer in violation of Section 15(a) of the Securities Exchange Act, and seeking rescission of convertible note transactions under Section 29(b). The complaint also alleges RICO violations based on collection of unlawful debt through criminally usurious loans under New York law, along with state law claims for unjust enrichment and constructive trust. Notably, this complaint does NOT allege violations of Section 10(b) or Rule 10b-5 - it is not a traditional securities fraud class action but rather a rescission action based on dealer registration violations and RICO claims based on usury.",
      "claim_rulings": [
        {
          "claim": "Count I - Rescission under Section 29(b) for violation of Section 15(a) (making transactions as unregistered dealer)",
          "ruling": "sustained",
          "scienter_analysis": "Not applicable. This claim does not require scienter analysis under the PSLRA. Section 15(a) dealer registration violations and Section 29(b) rescission claims do not have a scienter element. The complaint adequately alleges that FirstFire engaged in the business of buying and selling securities for its own account as part of a regular business (over 200 transactions with 89+ companies since 2015), that it used instrumentalities of interstate commerce, and that it was not registered as a dealer. These factual allegations are sufficient to state a claim for rescission under Section 29(b)."
        },
        {
          "claim": "Count II - Rescission under Section 29(b) for violation of Section 15(a) (performance of agreements as unregistered dealer)",
          "ruling": "sustained",
          "scienter_analysis": "Not applicable. Like Count I, this claim does not require scienter. The complaint adequately alleges that FirstFire performed the agreements by converting debt to stock and selling shares while operating as an unregistered dealer, using instrumentalities of interstate commerce. The detailed conversion history and sales allegations are sufficient to state this claim."
        },
        {
          "claim": "Count III - Section 20(a) Control Person Liability against Fireman (based on Section 15(a) violations)",
          "ruling": "sustained",
          "scienter_analysis": "Not applicable in the traditional PSLRA sense. This Section 20(a) claim is derivative of the Section 15(a) violations in Counts I and II, not a Section 10(b) violation. The complaint adequately alleges Fireman's control over FirstFire as managing member of FirstFire Capital Management LLC, his power to direct securities transactions, his personal negotiation and signing of the convertible notes, and his lack of good faith. Since the underlying Section 15(a) claims survive, this derivative control person claim also survives."
        },
        {
          "claim": "Count IV - RICO Section 1962(c) - Collection of Unlawful Debt",
          "ruling": "sustained",
          "scienter_analysis": "Not applicable under PSLRA standards. RICO claims for collection of unlawful debt under 18 U.S.C. § 1962(c) have different requirements than securities fraud claims. The complaint adequately alleges: (1) FirstFire is an enterprise under RICO; (2) Fireman is a culpable person who conducted the enterprise's affairs; (3) the loans charged interest rates exceeding twice the 25% maximum under New York criminal usury law (alleged rates of 291.52% APR and 61% APR); and (4) FirstFire is in the business of making such loans. The detailed calculations of effective interest rates including OID, conversion discounts, and commitment shares sufficiently allege unlawful debt collection."
        },
        {
          "claim": "Count V - Unjust Enrichment",
          "ruling": "sustained",
          "scienter_analysis": "Not applicable. This is a state law equitable claim that does not require scienter analysis. The complaint adequately alleges defendants received valuable benefits (stock and profits from sales), the benefits resulted from wrongful conduct, and defendants unjustly retained these benefits at plaintiff's expense."
        },
        {
          "claim": "Count VI - Constructive Trust",
          "ruling": "sustained",
          "scienter_analysis": "Not applicable. This is a state law equitable remedy that does not require scienter analysis. The complaint adequately alleges unjust enrichment, plaintiff's identifiable interest in the property, wrongful acquisition and detention, and that allowing retention would be inequitable."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 12664,
      "completion_tokens": 1105,
      "total_tokens": 13769
    },
    "case_id": "nysd_1_21-cv-11222"
  },
  {
    "model": "claude-opus",
    "model_id": "claude-opus-4-5-20251101",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "This securities class action complaint alleges that Wells Fargo and its executives (Sloan, Shrewsberry, Parker, Duke, and Scharf) made materially false and misleading statements about the bank's compliance with 2018 Consent Orders from the Federal Reserve, OCC, and CFPB. Plaintiffs allege defendants repeatedly told investors they had compliant plans in place and were 'executing' those plans, when in fact regulators had rejected the bank's Stage 1 Plan submissions multiple times as 'materially incomplete,' 'insufficient,' and merely 'plans for plans.' The complaint alleges defendants concealed rejection letters, extension requests, and stern regulatory rebukes while publicly assuring investors of compliance progress.",
      "claim_rulings": [
        {
          "claim": "Section 10(b) and Rule 10b-5 against Wells Fargo, Sloan, Parker, Duke, and Shrewsberry",
          "ruling": "sustained",
          "scienter_analysis": "The complaint adequately pleads scienter with particularized facts showing defendants' actual knowledge of falsity. Key facts supporting a strong inference of scienter include: (1) Defendants Sloan and Duke personally received formal rejection letters from the Federal Reserve on May 7, 2018 and March 11, 2019 stating the Stage 1 Plans were 'materially incomplete' and 'insufficient,' yet they continued to tell investors they were 'executing' approved plans; (2) Internal emails show Director Craver told Duke they 'totally biffed it' and that investors would find the rejection 'completely unacceptable'; (3) Defendant Sloan personally called the Federal Reserve to apologize for his 'mischaracterizations' after his March 2019 congressional testimony, yet never issued public corrections; (4) Defendants Sloan and Duke actively concealed the truth by agreeing to 'tone down the actual disclosures' and removing language about 'substantial amount of work remaining' from SEC filings; (5) The OCC informed the Board that Sloan's congressional testimony was 'inaccurate'; (6) Director Peetz testified she repeatedly warned the Board that submissions were 'not going far enough' and identified Sloan as 'a major impediment'; (7) Wells Fargo clawed back $15 million of Sloan's compensation due to his 'role and responsibility' for lack of regulatory progress; (8) Defendants requested multiple extensions for Stage 1 Plan submissions while publicly claiming they were 'implementing' approved plans. These particularized facts demonstrate defendants knew their public statements about compliance were false when made, not mere fraud by hindsight. The inference of fraudulent intent is cogent and at least as compelling as any innocent inference."
        },
        {
          "claim": "Section 20(a) Control Person Liability against Insider Defendants (Sloan, Shrewsberry, Parker, Duke, Scharf)",
          "ruling": "sustained",
          "scienter_analysis": "Because the underlying Section 10(b) claim survives, the Section 20(a) claim is sustained. The complaint adequately alleges each Insider Defendant was a controlling person of Wells Fargo by virtue of their positions as CEO, CFO, Board Chair, and directors, with direct involvement in regulatory compliance matters and the power to control public statements. The complaint alleges they were culpable participants who had primary responsibility for ensuring compliance with the 2018 Consent Orders, received rejection letters and regulatory feedback directly, and participated in issuing the false statements."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 57871,
      "completion_tokens": 794,
      "total_tokens": 58665
    },
    "case_id": "nysd_20_cv_04494"
  },
  {
    "model": "claude-opus",
    "model_id": "claude-opus-4-5-20251101",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "This securities class action alleges that Spectrum Pharmaceuticals and its executives (Riga, Lebel, and Brennan) made materially false and misleading statements during the Class Period (March 17, 2022 through September 22, 2022) regarding the company's drug poziotinib (pozi). Plaintiffs allege defendants misrepresented that: (1) they had 'optimized' the dosage for pozi when the FDA had repeatedly told them their dose optimization data was inadequate; (2) patients were 'being randomized' into the PINNACLE confirmatory study when no patients had actually enrolled; and (3) Spectrum was 'aligned' with the FDA on the PINNACLE Study design when the FDA had warned them they were proceeding 'at their own risk.' The complaint alleges defendants were motivated to mislead investors because Spectrum was in precarious financial condition and needed to raise cash through stock sales under an ATM agreement.",
      "claim_rulings": [
        {
          "claim": "Section 10(b) and Rule 10b-5 - Count I",
          "ruling": "sustained",
          "scienter_analysis": "The complaint adequately pleads scienter with particularized facts creating a strong inference of fraudulent intent. First, the complaint alleges specific meetings between defendants and the FDA (December 13, 2021; February 7, 2022; May 18, 2022; July 28, 2022; September 8, 2022) where FDA officials explicitly communicated concerns about inadequate dose optimization data, lack of agreement on PINNACLE Study design, and warnings that proceeding with 8mg BID was 'at their own risk.' These particularized allegations establish defendants' actual knowledge that their public statements about being 'aligned' with FDA and having 'optimized' dosing were false when made. Second, defendants made specific, verifiable misrepresentations that 'patients are being randomized' into PINNACLE when they knew no patients had enrolled - this is not fraud by hindsight but contemporaneous knowledge of falsity. Third, the complaint alleges concrete motive: Spectrum was running out of cash and defendants caused the company to sell over $9.4 million in stock under the ATM Agreement during the Class Period while making these misrepresentations. Individual defendants Lebel and Brennan also sold personal shares during this period. Fourth, the FDA's post-Class Period statements at the ODAC meeting confirm what defendants were told privately, including that Spectrum was 'rushing this development program,' that dose optimization failures were a 'fatal flaw,' and that the FDA 'did not come to any formal agreement about the 8-mg BID dose.' The inference of scienter is at least as compelling as any innocent inference - defendants with direct FDA communications made specific false statements about enrollment status and FDA alignment that were directly contradicted by what they were being told in private meetings."
        },
        {
          "claim": "Section 20(a) Control Person Liability - Count II",
          "ruling": "sustained",
          "scienter_analysis": "Because the underlying Section 10(b) and Rule 10b-5 claim is sustained, the derivative Section 20(a) claim against the Individual Defendants (Riga, Lebel, and Brennan) may proceed. The complaint adequately alleges that each Individual Defendant acted as a controlling person of Spectrum by virtue of their positions as senior executives (CEO, CMO, CFO) with power to control public statements to investors. The complaint alleges they possessed the power and authority to control the contents of SEC reports, press releases, and presentations to analysts and investors, and were provided copies of misleading statements prior to issuance with the ability to prevent or correct them."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 26932,
      "completion_tokens": 865,
      "total_tokens": 27797
    },
    "case_id": "nysd_22_cv_10292"
  },
  {
    "model": "claude-opus",
    "model_id": "claude-opus-4-5-20251101",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "This securities class action alleges that DocGo Inc. and its executives (Vashovsky, Capone, and Oberholzer) violated Sections 10(b) and 20(a) of the Securities Exchange Act by making materially false and misleading statements about: (1) CEO Capone's fabricated educational credentials, including a nonexistent graduate degree in computational learning theory from Clarkson University; (2) the value of a CBP contract, which Capone inflated from approximately $2 billion to 'over $4 billion'; and (3) false claims that DocGo had signed up over 3,000 migrants for New York State Medicaid through UnitedHealthcare when DocGo had no such contract with UnitedHealthcare in New York. The complaint alleges the stock price declined over 56% as these misrepresentations were revealed through a series of Times Union articles in September 2023, followed by Capone's immediate resignation.",
      "claim_rulings": [
        {
          "claim": "Section 10(b) and Rule 10b-5 violations against all defendants",
          "ruling": "sustained",
          "scienter_analysis": "The complaint adequately pleads scienter with particularized facts demonstrating actual knowledge of falsity. First, regarding Capone's educational credentials, Capone personally and repeatedly made false statements about his own graduate degree in computational learning theory - facts uniquely within his personal knowledge. He stated at multiple investor conferences that 'my grad degree is in computational learning theory' when he knew he had never enrolled in any graduate program. This is not fraud by hindsight; Capone necessarily knew whether he attended graduate school. His admission that he 'do[es] not have a master's degree from Clarkson University, nor from any other institution' confirms he knowingly misrepresented his credentials. Second, regarding the CBP contract value, Capone stated the contract was 'worth o[ve]r $4 billion' when multiple sources confirmed it was worth no more than $2 billion. As CEO overseeing operations with 'access to information concerning the value of contracts in DocGo's pipeline,' Capone either knew or recklessly disregarded the true contract value. Third, Capone stated DocGo had 'signed up over 3,000 asylum seekers onto New York State Medicaid through United Healthcare' when DocGo later admitted it 'does not enroll anyone in Medicaid programs' and had no contract with UnitedHealthcare in New York. These are not matters requiring inference - they are direct falsehoods about facts within the speaker's knowledge. For Vashovsky and Oberholzer, the complaint alleges they signed proxy statements and SEC filings containing false representations about Capone's educational credentials without verifying them, and as senior executives with access to internal information, they knew or recklessly disregarded the falsity of these statements."
        },
        {
          "claim": "Section 20(a) control person liability against all defendants",
          "ruling": "sustained",
          "scienter_analysis": "Because the underlying Section 10(b) claim is sustained, the Section 20(a) claim survives. The complaint adequately alleges that the Individual Defendants were controlling persons by virtue of their positions as senior executive officers and/or directors who had the power to influence and control the Company's decision-making, including the content and dissemination of the allegedly false statements. Vashovsky served as CEO until January 2023 and remained Chairman; Capone served as President and then CEO; Oberholzer served as CFO and later as Treasurer and Executive VP. Each had direct or supervisory responsibility over day-to-day operations and the preparation of public filings."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 17775,
      "completion_tokens": 831,
      "total_tokens": 18606
    },
    "case_id": "nysd_23_cv_9476"
  },
  {
    "model": "claude-opus",
    "model_id": "claude-opus-4-5-20251101",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "This securities class action alleges that Mobileye Global Inc. and its executives made materially false and misleading statements about the company's EyeQ chip sales, revenue growth, and customer demand. Plaintiffs allege defendants engaged in a channel stuffing scheme by forcing Tier 1 customers into minimum purchase commitments that made it 'impossible' to adjust orders to actual market demand, resulting in 6-7 million excess EyeQ chips shipped over several years. The complaint alleges defendants concealed this practice while touting record sales and growth, and when the truth emerged in January 2024, the stock price collapsed approximately 70%.",
      "claim_rulings": [
        {
          "claim": "Section 10(b) and Rule 10b-5(b) - Material Misstatements (Count I)",
          "ruling": "sustained",
          "scienter_analysis": "The complaint adequately pleads scienter with particularized facts. First, FE 2, a former VP of ADAS Business Development who reported to an executive directly under CEO Shashua, stated that the decision to push inventory to Tier 1 customers 'went up to Amnon' (Shashua), and that CFO Heller attended quarterly meetings where issues with Tier 1 customers and their reports were discussed. Second, defendants personally and repeatedly spoke about inventory levels, customer commitments, and demand matching throughout the Class Period, demonstrating their direct involvement with and knowledge of these subjects. Third, defendants admitted they imposed annual minimum commitments that made it 'impossible' for customers to adjust quantities - defendants necessarily knew the terms of contracts they imposed on their largest customers generating 70% of revenue. Fourth, industry-standard EDI communications and forecasts from Tier 1 customers provided defendants with regular data showing the gap between shipments and actual demand. Fifth, the scheme enabled Mobileye to precisely meet guidance and analyst expectations each quarter - without excess inventory sales, the company would have missed every quarterly consensus and annual guidance. The core operations doctrine applies given EyeQ chips comprised approximately 90% of revenue. The inference of scienter is at least as compelling as any innocent inference."
        },
        {
          "claim": "Section 10(b) and Rules 10b-5(a) and (c) - Scheme Liability (Count II)",
          "ruling": "sustained",
          "scienter_analysis": "The complaint adequately pleads a scheme to defraud with the requisite scienter. The alleged scheme involved: (1) forcing customers into annual minimum purchase commitments that made adjustment to market conditions 'impossible'; (2) shipping millions of excess EyeQ chips over several years despite customer objections; (3) concealing these practices while publicly assuring investors that shipments depended on 'market conditions'; and (4) falsely attributing the scheme's eventual fallout to customer decisions rather than Mobileye's own conduct. FE 2's testimony that the decision to push inventory 'went up to Amnon' (CEO Shashua), combined with FE 1's account that Mobileye 'forced us to make overstock' despite Aptiv's objections, provides particularized facts showing defendants knowingly engaged in deceptive conduct. The scheme was not merely a business practice but was designed to inflate reported revenue and meet financial targets while concealing the true state of demand."
        },
        {
          "claim": "Section 20(a) Control Person Liability (Count III)",
          "ruling": "sustained",
          "scienter_analysis": "Because the underlying Section 10(b) and Rule 10b-5 claims are sustained, the Section 20(a) control person claims against the Executive Defendants (Shashua, Rojansky, Heller, and Galves) may proceed. The complaint adequately alleges that these individuals were controlling persons by virtue of their positions as CEO, CFOs, and Chief Communications Officer, with direct involvement in the company's operations and public statements. Each defendant made public statements during the Class Period and had the authority to control the content of Mobileye's disclosures."
        },
        {
          "claim": "Section 11 of the Securities Act (Count IV)",
          "ruling": "sustained",
          "scienter_analysis": "Section 11 claims are strict liability claims that do not require scienter allegations. The complaint adequately alleges that the Offering Documents for the June 2023 Secondary Public Offering contained material misstatements and omissions regarding: (1) the nature and extent of minimum quantity commitments with customers; (2) the fact that Mobileye had already shipped 4-5 million excess EyeQ chips by the time of the Offering; (3) that volumes shipped did not depend on 'market conditions' as represented; and (4) the failure to disclose material adverse trends as required by Items 303 and 105 of Regulation S-K. Oklahoma Firefighters has standing as a direct purchaser in the Offering."
        },
        {
          "claim": "Section 15 of the Securities Act (Count V)",
          "ruling": "sustained",
          "scienter_analysis": "Section 15 control person liability does not require scienter. Because the Section 11 claim is sustained, the Section 15 claims against Shashua and Heller may proceed. Both signed the Registration Statement and, as CEO and CFO respectively, were controlling persons of Mobileye with the ability to control the contents of the Offering Documents."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 49738,
      "completion_tokens": 1265,
      "total_tokens": 51003
    },
    "case_id": "nysd_24_cv_310"
  },
  {
    "model": "claude-opus",
    "model_id": "claude-opus-4-5-20251101",
    "test": "test3",
    "success": true,
    "response": {
      "summary": "This securities class action alleges that American Airlines and its executives (Isom, May, and Raja) made materially false and misleading statements about the company's 'Modern Retailing' distribution strategy that pushed customers toward NDC (New Distribution Capability) channels and away from traditional EDIFACT booking channels. Plaintiffs allege defendants knew the strategy was driving away travel agencies and corporate customers, causing American to lose market share to competitors, but continued to tout the strategy's success and issue false earnings guidance until May 2024 when they disclosed the truth, causing a 13.5% stock drop.",
      "claim_rulings": [
        {
          "claim": "Section 10(b) and Rule 10b-5 - Securities Fraud",
          "ruling": "sustained",
          "scienter_analysis": "The complaint adequately pleads scienter with particularized facts supporting a strong inference of fraudulent intent. First, confidential witnesses (CW1 and CW2) provide specific, contemporaneous accounts that defendants had access to internal data (SalesLink Insights, PRISM reports, IATA data) showing declining bookings and market share from July 2023 onward. CW2 states bookings from larger agencies declined 15% year-over-year immediately after the July 2023 contracts, with corporate bookings 'much lower,' and these metrics remained 'consistently down.' Second, defendant Isom's post-class period admission is devastating: he stated 'we identified a deviation in terms of our revenue performance versus some of our large network peers in the first quarter. We thought that was going to reverse itself. It didn't.' This admission establishes actual knowledge of underperformance during the class period. Third, the engagement of Bain & Co. to conduct a 'critical review' of the distribution strategy weeks before the corrective disclosure indicates defendants knew of serious problems. Fourth, the magnitude of the concealed harm ($750 million revenue impact in the first half of 2024 alone) combined with the core operations doctrine supports scienter - this was central to American's business. Fifth, defendant Raja's evasive responses when directly asked about market share shifts and 'growing pains' during earnings calls suggest conscious avoidance. The motive to maintain stock price during a strategic transition, combined with the temporal proximity between defendants' knowledge of problems and their contradictory public statements, creates a strong inference of scienter that is at least as compelling as any innocent inference."
        },
        {
          "claim": "Section 20(a) - Control Person Liability",
          "ruling": "sustained",
          "scienter_analysis": "Because the Section 10(b) claim survives, the derivative Section 20(a) claim against the Individual Defendants (Isom, May, and Raja) also survives. The complaint adequately alleges that each Individual Defendant was a controlling person by virtue of their senior executive positions (CEO, CFO, and CCO respectively), their direct participation in making the alleged misstatements, their access to internal data contradicting their public statements, and their authority over the company's public communications. Defendant Isom himself admitted 'our strategy is the company strategy. Those are my strategies,' establishing his control over the distribution strategy at issue."
        }
      ]
    },
    "usage": {
      "prompt_tokens": 60471,
      "completion_tokens": 708,
      "total_tokens": 61179
    },
    "case_id": "txnd-4_24-cv-00673"
  }
]